Broadband wireless repeater for mobile communication system
    102.
    发明申请
    Broadband wireless repeater for mobile communication system 审中-公开
    用于移动通信系统的宽带无线中继器

    公开(公告)号:US20050227619A1

    公开(公告)日:2005-10-13

    申请号:US10343409

    申请日:2002-09-17

    IPC分类号: H04B7/155 H04B7/14 H04B7/26

    CPC分类号: H04B7/15578 H04B7/2606

    摘要: Disclosed herewith is a broadband wireless repeater for a mobile communication system. The broadband wireless repeater generally includes a transmission stage and a receiving stage. The transmission stage includes an RF switch for establishing a frequency path, an Intermediate Frequency delay unit for applying delay to IFs and bypassing the IF delay, a frequency up conversion modulator, an amplifier, a filter unit for eliminating undesired band signals, and a transmitting side antenna. The receiving stage includes an array antenna, a band-pass filter unit for eliminating undesired band signals, an amplifier, a phase shifter for controlling phases of channels, a frequency down conversion modulator, a phase comparison unit, a gain comparison unit, a vector value optimizer for decreasing errors of the main signals with a maximum output, and a synthesizing module for detecting and storing output levels of the channels.

    摘要翻译: 本文公开了一种用于移动通信系统的宽带无线中继器。 宽带无线中继器通常包括传输级和接收级。 传输级包括用于建立频率路径的RF开关,用于向IF施加延迟并绕过IF延迟的中频延迟单元,升频转换调制器,放大器,用于消除不期望的频带信号的滤波器单元,以及发送 侧天线。 接收级包括阵列天线,用于消除不需要的频带信号的带通滤波器单元,放大器,用于控制信道相位的移相器,降频转换调制器,相位比较单元,增益比较单元,矢量 用于减少具有最大输出的主信号的误差的值优化器,以及用于检测和存储信道的输出电平的合成模块。

    Synthesis of nanosized metal particles
    103.
    发明申请
    Synthesis of nanosized metal particles 有权
    纳米金属颗粒的合成

    公开(公告)号:US20050217429A1

    公开(公告)日:2005-10-06

    申请号:US10814151

    申请日:2004-04-01

    IPC分类号: B22F1/00 B22F9/24

    摘要: The present invention is directed to methods for forming nanosized metal particles. Preferably, nanosized noble metal particles are formed. According to the methods of the invention, a product containing nanosized metal particles in a solvent are formed. Additionally, processing to remove undesirable byproducts created or used during the fabrication process are not necessary.

    摘要翻译: 本发明涉及形成纳米尺寸金属颗粒的方法。 优选地,形成纳米尺寸的贵金属颗粒。 根据本发明的方法,形成在溶剂中含有纳米尺寸金属颗粒的产品。 此外,不需要在制造过程中产生或使用的去除不期望的副产物的处理。

    Multi-chip assembly and method for driving the same
    104.
    发明申请
    Multi-chip assembly and method for driving the same 审中-公开
    多芯片组装及其驱动方法

    公开(公告)号:US20050151237A1

    公开(公告)日:2005-07-14

    申请号:US10999415

    申请日:2004-11-30

    申请人: Kwi Kim Chang Lee

    发明人: Kwi Kim Chang Lee

    摘要: Disclosed are a multi-chip assembly and a method for driving the same. The multi-chip assembly includes a first chip designed with a first device driven by a first power source and a second chip designed with a second device driven by a second power source. A power applying section applies first power to the first device of the first chip and a power converting section converts the first power to second power upon receiving the first power from the power applying section and applies the second power to the second device of the second chip. It is possible to provide the multi-chip assembly in the form of a package fabricated by stacking chips designed with mutually different devices driven through a single power source.

    摘要翻译: 公开了一种多芯片组件及其驱动方法。 多芯片组件包括设计有由第一电源驱动的第一设备的第一芯片和设计有由第二电源驱动的第二设备的第二芯片。 功率施加部将第一功率施加到第一芯片的第一装置,并且功率转换部从接收到来自功率施加部的第一功率将第一功率转换为第二功率,并将第二功率施加到第二芯片的第二装置 。 可以提供通过堆叠设计成通过单个电源驱动的相互不同的器件的芯片制造的封装形式的多芯片组件。

    Treating Auto-Immune and Auto-Inflammatory Diseases
    105.
    发明申请
    Treating Auto-Immune and Auto-Inflammatory Diseases 审中-公开
    治疗自身免疫和自身炎症

    公开(公告)号:US20160045517A1

    公开(公告)日:2016-02-18

    申请号:US14860680

    申请日:2015-09-21

    申请人: Tao Tom Du Chang Lee

    发明人: Tao Tom Du Chang Lee

    IPC分类号: A61K31/573 A61K9/00 A61K31/58

    摘要: The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17α-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.

    摘要翻译: 本发明涉及减少支气管肺泡灌洗液(BALF)和血液/血清中和/或抑制p38丝裂原活化蛋白的细胞因子白细胞介素-17(IL-17或IL-17A)水平的制剂,方法和试剂盒 涉及使用17α-羟孕酮己酸酯(17-OHPC)或其衍生物的激酶(MAPK)活性。 制剂可以是含有有效量的17-OHPC的吸入剂的形式,并且该制剂可用于治疗IL-17细胞因子和/或p38MAPK介导的自身免疫和自身炎性疾病的方法。 这些疾病可能包括糖皮质激素(GC)不敏感的相关疾病或病症。 在替代实施方案中,制剂可以包括布地奈德(BUD)与17-OPHC的组合使用。

    Pulmonary Delivery of Progestogen
    106.
    发明申请
    Pulmonary Delivery of Progestogen 审中-公开
    孕激素的肺部输送

    公开(公告)号:US20160045396A1

    公开(公告)日:2016-02-18

    申请号:US14860578

    申请日:2015-09-21

    申请人: Chang Lee Tao Tom Du

    发明人: Chang Lee Tao Tom Du

    摘要: The present invention relates to a pharmaceutical formulation powder that contains 17α-hydroxyprogesterone caproate (17-OHPC) powder and the method of producing the formulation produces particles that are suitable as an inhalant. The formulations, methods and kits of powdered 17-OHPC as taught herein may be used to reduce cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and involve the inhibition of p38 mitogen activating protein kinase (MAPK) activity. The 17-OHPC powder formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) and/or fluticasone with 17-OPHC.

    摘要翻译: 本发明涉及含有17α-羟基孕酮己酸酯(17-OHPC)粉末的药物制剂粉末,并且制备该制剂的方法产生适合作为吸入剂的颗粒。 本文教导的粉末状17-OHPC的制剂,方法和试剂盒可用于减少支气管肺泡灌洗液(BALF)和血液/血清中的细胞因子白细胞介素-17(IL-17或IL-17A)水平,并且涉及抑制 p38丝裂原活化蛋白激酶(MAPK)活性。 17-OHPC粉末制剂可用于治疗IL-17细胞因子和/或p38MAPK介导的自身免疫和自身炎症性疾病的方法。 这些疾病可能包括糖皮质激素(GC)不敏感的相关疾病或病症。 在替代实施方案中,制剂可以包括布地奈德(BUD)和/或氟替卡松与17-OPHC的组合使用。